Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 771 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anemia, Sickle Cell Clear all
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 9, 2026, 9:15 AM EDT
Completed No phase listed Observational

Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease

NCT01959958
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Questionnaire/Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 9, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

NCT02105766
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
Interventions
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy, Filgrastim
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Completed No phase listed Observational

Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers Study (INSIGHTS Study)

NCT02156102
View directory record Official record
Conditions
Genetic Disease, Genomics
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 9, 2026, 9:15 AM EDT
Completed No phase listed Observational

Retrospective Real World Oxbryta® Data Collection and Analysis Study

NCT04930328
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oxbryta® (voxelotor) 500-mg Tablets
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Farmington, Connecticut • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

NCT05861453
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Epeleuton
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

NCT06555939
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Collaborative Care Model, Promoting Resilience in Stress Management
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease
Interventions
Fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

NCT01090323
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Sep 9, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Flow and Pain Crises in People With Sickle Cell Disease

NCT01568710
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 9, 2026, 9:15 AM EDT
Enrolling by invitation No phase listed Observational

SCRIPT: Sickle Cell Risk in Pregnancy Tool

NCT06529042
View directory record Official record
Conditions
Sickle Cell Disease, Pregnancy, High Risk, Pregnancy Complications
Interventions
Non-Interventional
Other
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease

NCT02857023
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Cogmed RM
Behavioral
Lead sponsor
Steven J. Hardy
Other
Eligibility
7 Years to 16 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Not applicable Interventional

A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

NCT04484272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support])., Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT03333486
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

NCT00004492
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 9, 2026, 9:15 AM EDT
Recruiting No phase listed Observational

A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease

NCT04166526
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
FDNIRS-DCS, MRI
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 9, 2026, 9:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Ovarian Reserve in Sickle Cell Disease

NCT07392216
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2034
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Systemic/High Local Exercise Load in Peds SCD

NCT06387758
View directory record Official record
Conditions
Sickle Cell Anemia in Children
Interventions
Low systemic strength training, Moderate systemic exercise
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 9, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

NCT06773715
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions
KindVR Aqua Program
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
8 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 9, 2026, 9:15 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients

NCT07217548
View directory record Official record
Conditions
Stigma
Interventions
point of view simulation, Control
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Disease
Interventions
Saline, MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 9, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia

NCT00001716
View directory record Official record
Conditions
Chest Pain, Sickle Cell Anemia
Interventions
Nitric Oxide, Nitroglycerin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 9:15 AM EDT